Little is expected to change at the US FDA in terms of CBD or cannabis policy if president Donald Trump’s nominee Stephen Hahn is approved as commissioner, according to sources contacted by CBD-Intel
Written by CannIntelligence || 6th November 2019 || News analysis | Policy and Politics | Regulation and legislation | North America United States